Lyra Therapeutics, Inc.
corporate_fare Company Profile
Lyra Therapeutics, Inc. (OTC:LYRA) is a publicly traded company in the Healthcare sector. Wiseek has independently scored 8 items for LYRA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-04-17, rated 9/10. Across its 8 most recent items scored 7 or higher, the top rating is 10/10, with 8 rated 8 or above. Recent SEC coverage for LYRA spans 8-K, 10-K.
Recent high-impact activity:
- Lyra Therapeutics Incurs $2.1M Termination Fee for Another Sublease Amid Liquidation
- Lyra Therapeutics Incurs $3.9M in Lease Termination Costs Amidst Unwinding Operations
- Lyra Halts All Drug Programs, Initiates Strategic Review Amid Delisting and Cash Crunch
- Lyra Therapeutics Delisted from Nasdaq, Declared 'Public Shell' Amid R&D Suspension and Liquidation Efforts
- Lyra Therapeutics Confirms Nasdaq Delisting, Trading Suspension Imminent
Financial Snapshot
Short Interest & Short Volume
1.82 days to coverFINRA reported short interest of 4,816 shares in LYRA as of the October 30, 2026 settlement, a 0.1% decrease from the prior period — about 1.8 days to cover at its recent average daily volume.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.